Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Bollag, Gideon

Class:Id	Person:5658261
_displayName	Bollag, Gideon
_timestamp	2014-12-18 17:01:59
created	[InstanceEdit:5658260] Rothfels, Karen, 2014-12-18
firstname	Gideon
initial	G
surname	Bollag
(author)	[LiteratureReference:5658427] Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells [LiteratureReference:5658436] Ras regulation. NF is enough of GAP [LiteratureReference:5658443] The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 [LiteratureReference:6790237] Biochemical and functional characterization of germ line KRAS mutations [LiteratureReference:6790292] Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity [LiteratureReference:6790346] Germline KRAS mutations cause Noonan syndrome [LiteratureReference:6790390] RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF [LiteratureReference:9656978] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [LiteratureReference:9690171] An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling [LiteratureReference:9703039] Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
[Change default viewing format]

No pathways have been reviewed or authored by Bollag, Gideon (5658261)